A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
BACKGROUND: Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Text |
| Language: | English |
| Published: |
BioMed Central
2006
|
| Subjects: | |
| Online Access: | https://pmc.ncbi.nlm.nih.gov/articles/PMC1712353/ https://pubmed.ncbi.nlm.nih.gov/17150109 http://dx.doi.org/10.1186/1471-2407-6-278 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|